---
document_datetime: 2025-11-23 07:01:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vizarsin.html
document_name: vizarsin.html
version: success
processing_time: 0.1108407
conversion_datetime: 2025-12-26 10:01:11.826698
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vizarsin

[RSS](/en/individual-human-medicine.xml/66035)

##### Authorised

This medicine is authorised for use in the European Union

sildenafil

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Vizarsin. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vizarsin.

Expand section

Collapse section

## What is Vizarsin?

Vizarsin is a medicine that contains the active substance sildenafil. It is available as film-coated tablets (25, 50 and 100 mg) and as orodispersible tablets (25, 50 and 100 mg). Orodispersible means that the tablet dissolves in the mouth.

Vizarsin is a 'generic medicine'. This means that Vizarsin is similar to a 'reference medicine' already authorised in the European Union (EU) called Viagra.

## What is Vizarsin used for?

Vizarsin is used to treat adult men with erectile dysfunction (sometimes called impotence), when they cannot get or keep a hard penis (erection) sufficient for satisfactory sexual activity. For Vizarsin to be effective, sexual stimulation is required.

The medicine can only be obtained with a prescription.

## How is Vizarsin used?

The recommended dose of Vizarsin is 50 mg taken as needed about one hour before sexual activity. If Vizarsin is taken with food, the onset of activity may be delayed compared with taking Vizarsin without food. The dose may be increased to a maximum of 100 mg or decreased to 25 mg depending on the effectiveness and side effects. Patients with reduced liver or severely reduced kidney function should start treatment with the 25-mg dose. The maximum recommended dosing frequency is one tablet per day.

## How does Vizarsin work?

The active ingredient in Vizarsin, sildenafil, belongs to a group of medicines called phosphodiesterase-type-5 (PDE5) inhibitors. It works by blocking the phosphodiesterase enzyme, which normally breaks down a substance known as cyclic guanosine monophosphate (cGMP). During normal sexual stimulation, cGMP is produced in the penis, where it causes the muscle in the spongy tissue of the penis (the corpora cavernosa) to relax. This allows blood to flow into the corpora, producing the erection. By blocking the breakdown of cGMP, Vizarsin restores erectile function. Sexual stimulation is still needed to produce an erection.

## How has Vizarsin been studied?

Because Vizarsin is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Viagra. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefit and risk of Vizarsin?

Because Vizarsin is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.

## Why has Vizarsin been approved?

The CHMP concluded that, in accordance with EU requirements, Vizarsin has been shown to have comparable quality and to be bioequivalent to Viagra. Therefore, the CHMP's view was that, as for Viagra, the benefit outweighs the identified risk. The Committee recommended that Vizarsin be given marketing authorisation.

## Other information about Vizarsin

The European Commission granted a marketing authorisation valid throughout the European Union for Vizarsin on 21 September 2009.

For more information about treatment with Vizarsin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Vizarsin : EPAR - Summary for the public

English (EN) (47.49 KB - PDF)

**First published:** 09/10/2009

**Last updated:** 09/07/2012

[View](/en/documents/overview/vizarsin-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-623)

български (BG) (95.71 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/bg/documents/overview/vizarsin-epar-summary-public_bg.pdf)

español (ES) (108.48 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/es/documents/overview/vizarsin-epar-summary-public_es.pdf)

čeština (CS) (75.13 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/cs/documents/overview/vizarsin-epar-summary-public_cs.pdf)

dansk (DA) (110.01 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/da/documents/overview/vizarsin-epar-summary-public_da.pdf)

Deutsch (DE) (50.59 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/de/documents/overview/vizarsin-epar-summary-public_de.pdf)

eesti keel (ET) (49.15 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/et/documents/overview/vizarsin-epar-summary-public_et.pdf)

ελληνικά (EL) (146.09 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/el/documents/overview/vizarsin-epar-summary-public_el.pdf)

français (FR) (66.08 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/fr/documents/overview/vizarsin-epar-summary-public_fr.pdf)

italiano (IT) (50.01 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/it/documents/overview/vizarsin-epar-summary-public_it.pdf)

latviešu valoda (LV) (86.78 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/lv/documents/overview/vizarsin-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (73.43 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/lt/documents/overview/vizarsin-epar-summary-public_lt.pdf)

magyar (HU) (131.32 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/hu/documents/overview/vizarsin-epar-summary-public_hu.pdf)

Malti (MT) (74.35 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/mt/documents/overview/vizarsin-epar-summary-public_mt.pdf)

Nederlands (NL) (109.61 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/nl/documents/overview/vizarsin-epar-summary-public_nl.pdf)

polski (PL) (75.81 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/pl/documents/overview/vizarsin-epar-summary-public_pl.pdf)

português (PT) (49.87 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/pt/documents/overview/vizarsin-epar-summary-public_pt.pdf)

română (RO) (72.71 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/ro/documents/overview/vizarsin-epar-summary-public_ro.pdf)

slovenčina (SK) (133.32 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/sk/documents/overview/vizarsin-epar-summary-public_sk.pdf)

slovenščina (SL) (129.92 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/sl/documents/overview/vizarsin-epar-summary-public_sl.pdf)

Suomi (FI) (49.54 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/fi/documents/overview/vizarsin-epar-summary-public_fi.pdf)

svenska (SV) (109.68 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

09/07/2012

[View](/sv/documents/overview/vizarsin-epar-summary-public_sv.pdf)

## Product information

Vizarsin : EPAR - Product Information

English (EN) (1.32 MB - PDF)

**First published:** 09/10/2009

**Last updated:** 24/02/2023

[View](/en/documents/product-information/vizarsin-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-229)

български (BG) (2.13 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/bg/documents/product-information/vizarsin-epar-product-information_bg.pdf)

español (ES) (1.55 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/es/documents/product-information/vizarsin-epar-product-information_es.pdf)

čeština (CS) (1.55 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/cs/documents/product-information/vizarsin-epar-product-information_cs.pdf)

dansk (DA) (1.35 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/da/documents/product-information/vizarsin-epar-product-information_da.pdf)

Deutsch (DE) (1.99 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/de/documents/product-information/vizarsin-epar-product-information_de.pdf)

eesti keel (ET) (1.77 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/et/documents/product-information/vizarsin-epar-product-information_et.pdf)

ελληνικά (EL) (1.84 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/el/documents/product-information/vizarsin-epar-product-information_el.pdf)

français (FR) (2.02 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/fr/documents/product-information/vizarsin-epar-product-information_fr.pdf)

hrvatski (HR) (1.33 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/hr/documents/product-information/vizarsin-epar-product-information_hr.pdf)

íslenska (IS) (1.56 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/is/documents/product-information/vizarsin-epar-product-information_is.pdf)

italiano (IT) (1.55 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/it/documents/product-information/vizarsin-epar-product-information_it.pdf)

latviešu valoda (LV) (1.55 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/lv/documents/product-information/vizarsin-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.55 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/lt/documents/product-information/vizarsin-epar-product-information_lt.pdf)

magyar (HU) (555.96 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/hu/documents/product-information/vizarsin-epar-product-information_hu.pdf)

Malti (MT) (618.5 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/mt/documents/product-information/vizarsin-epar-product-information_mt.pdf)

Nederlands (NL) (532.19 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/nl/documents/product-information/vizarsin-epar-product-information_nl.pdf)

norsk (NO) (1.55 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/no/documents/product-information/vizarsin-epar-product-information_no.pdf)

polski (PL) (536.85 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/pl/documents/product-information/vizarsin-epar-product-information_pl.pdf)

português (PT) (513.28 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/pt/documents/product-information/vizarsin-epar-product-information_pt.pdf)

română (RO) (1.78 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/ro/documents/product-information/vizarsin-epar-product-information_ro.pdf)

slovenčina (SK) (1.56 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/sk/documents/product-information/vizarsin-epar-product-information_sk.pdf)

slovenščina (SL) (493.77 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/sl/documents/product-information/vizarsin-epar-product-information_sl.pdf)

Suomi (FI) (1.55 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/fi/documents/product-information/vizarsin-epar-product-information_fi.pdf)

svenska (SV) (1.34 MB - PDF)

**First published:**

09/10/2009

**Last updated:**

24/02/2023

[View](/sv/documents/product-information/vizarsin-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0036 22/02/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vizarsin : EPAR - All Authorised presentations

English (EN) (17.96 KB - PDF)

**First published:** 09/10/2009

**Last updated:** 11/08/2016

[View](/en/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-742)

български (BG) (44.75 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/bg/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_bg.pdf)

español (ES) (20.03 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/es/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_es.pdf)

čeština (CS) (32.32 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/cs/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (21.51 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/da/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (35.18 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/de/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (21.24 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/et/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (44.41 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/el/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_el.pdf)

français (FR) (22.43 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/fr/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (49.39 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/hr/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (21.07 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/is/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_is.pdf)

italiano (IT) (22.17 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/it/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (43.02 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/lv/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (43.21 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/lt/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (36.23 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/hu/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (41.52 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/mt/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (22.38 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/nl/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (21.09 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/no/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_no.pdf)

polski (PL) (39.25 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/pl/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_pl.pdf)

português (PT) (21.87 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/pt/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_pt.pdf)

română (RO) (38.81 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/ro/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (39.96 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/sk/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (29.46 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/sl/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (22.1 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/fi/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (21.57 KB - PDF)

**First published:**

09/10/2009

**Last updated:**

11/08/2016

[View](/sv/documents/all-authorised-presentations/vizarsin-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vizarsin Active substance sildenafil International non-proprietary name (INN) or common name sildenafil Therapeutic area (MeSH) Erectile Dysfunction Anatomical therapeutic chemical (ATC) code G04BE03

### Pharmacotherapeutic group

Urologicals

### Therapeutic indication

Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.

In order for Vizarsin to be effective, sexual stimulation is required.

## Authorisation details

EMA product number EMEA/H/C/001076

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Krka, d.d., Novo mesto

Šmarješka cesta 6

Opinion adopted 25/06/2009 Marketing authorisation issued 21/09/2009 Revision 19

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vizarsin : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (154.9 KB - PDF)

**First published:** 27/08/2010

**Last updated:** 24/02/2023

[View](/en/documents/procedural-steps-after/vizarsin-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Vizarsin-H-C-1076-X-06 : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/351597/2012

English (EN) (212.58 KB - PDF)

**First published:** 09/07/2012

**Last updated:** 09/07/2012

[View](/en/documents/variation-report/vizarsin-h-c-1076-x-06-epar-assessment-report-extension_en.pdf)

## Initial marketing authorisation documents

Vizarsin : EPAR - Public assessment report

English (EN) (189.96 KB - PDF)

**First published:** 12/10/2009

**Last updated:** 12/10/2009

[View](/en/documents/assessment-report/vizarsin-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Vizarsin

Reference Number: EMEA/CHMP/372528/2009

English (EN) (33.44 KB - PDF)

**First published:** 24/06/2009

**Last updated:** 24/06/2009

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vizarsin_en.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 24/02/2023

## Share this page

[Back to top](#main-content)